Prakash Satwani
A5048733835- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Polyomavirus and related diseases
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immunodeficiency and Autoimmune Disorders
- Virus-based gene therapy research
- Prenatal Screening and Diagnostics
- Autoimmune and Inflammatory Disorders Research
- Neonatal Respiratory Health Research
- Transplantation: Methods and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Mesenchymal stem cell research
- Chronic Lymphocytic Leukemia Research
- Hematological disorders and diagnostics
- Neonatal Health and Biochemistry
Columbia University
2015-2025
Columbia University Irving Medical Center
2016-2025
New York Hospital Queens
2006-2024
NewYork–Presbyterian Hospital
2006-2024
Pediatrics and Genetics
2004-2021
Morgan Stanley Children's Hospital
2008-2021
Mahatma Gandhi Memorial Medical College
2020-2021
In-Q-Tel
2015
Presbyterian Hospital
2004-2013
Naval Medical Center Portsmouth
2013
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) time. This study used central database Center for International Blood Marrow Transplant Research (CIBMTR) to describe time cGVHD incidence, nonrelapse mortality, risk factors cGVHD. The 12-year period was divided into 3 intervals, 1995 1999, 2000 2003, 2004 2007, included 26,563 patients with acute leukemia, myeloid...
Tisagenlecleucel is a CD19-specific chimeric antigen receptor T-cell therapy, US Food and Drug Administration-approved for children, adolescents, young adults (CAYA) with relapsed and/or refractory (RR) B-cell acute lymphoblastic leukemia (B-ALL). The Administration registration tisagenlecleucel was based on complete response (CR) rate of 81%, 12-month overall survival (OS) 76%, event-free (EFS) 50%. We report clinical outcomes analyze covariates after commercial tisagenlecleucel.We...
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) following hematopoietic cell transplantation (HSCT) is associated with poor clinical outcomes. Currently, there are no safe and effective therapies approved for use in the pediatric population under age of 12 years. Accordingly, an urgent need new treatments that safe, well tolerated, managing this debilitating potentially fatal complication HSCT. In early phase trials, mesenchymal stromal cells (MSCs) have demonstrated efficacy...
Abstract Purpose Pediatric oncology patients undergoing active chemotherapy are suspected to be at a high risk for severe disease secondary acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection; however, data support this lacking. We aim describe the characteristics of coronavirus 2019 (COVID‐19) in population and also its impact on pediatric cancer care New York region during peak pandemic. Patients Methods This multicenter, retrospective study included 13 institutions. Clinical...
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves immune reconstitution, resulting lower nonrelapse mortality and increased survival. We hypothesized that lymphodepleting chemotherapy before CAR T-cell therapy would improve outcomes. retrospective analysis of patients with relapsed/refractory...
Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse rates of 14.5% 28%, respectively, whereas use in real-world setting showed 15% 37%. Outcome analyses describing fate post-CAR remain limited. Here, we aim establish outcomes both CD19+ CD19- relapses explore treatment variables associated with inferior survival.
Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Administration approved for relapsed or refractory B-ALL in patients ≤25 years; however, the safety efficacy this therapy young largely unknown children <3 years age were excluded from licensing studies. We retrospectively evaluated data Pediatric...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with myeloablative conditioning is associated a 10%-40% risk of day +100 transplantation-related mortality (TRM). We evaluated the feasibility and safety reduced-toxicity allo-HSCT in 100 consecutive children adolescent recipients (mean age, 9.2 ± 6.8 years). The mean duration follow-up was 1278 1042 days. Fifty patients had malignant disease. median time to neutrophil recovery 18 days, platelet 43 Median donor chimerism...
Sickle cell disease (SCD) is a hereditary hemoglobinopathy that affects over 100,000 people in the United States. Patients with SCD are known to experience suboptimal health-related quality of life (HRQoL). In addition physical manifestations SCD, psychological and social stress, along academic difficulties, secondary chronicity its complications often affect patients SCD. Although medical therapy has improved, allogeneic hematopoietic transplantation (allo-HCT) remains only curative...
Clinical outcomes in children with steroid-refractory acute graft-versus-host disease (SR-aGVHD) are generally poor, a high mortality rate and limited therapeutic options. Here we report our updated investigational experience mesenchymal stromal cell (MSC) therapy remestemcel-L multicenter expanded access protocol (ClinicalTrials.gov identifier NCT00759018) 241 aGVHD who failed to respond steroids or without other secondary tertiary immunosuppressive therapies. A total of grade B-D SR-aGVHD...
Chimeric antigen receptor (CAR) T cells have transformed the therapeutic options for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia. Data CAR therapy in extramedullary (EM) involvement are limited. Retrospective data were abstracted from Pediatric Real World Consortium (PRWCC) of 184 infused patients 15 US institutions. Response (complete response) rate, overall survival (OS), relapse-free (RFS), and duration aplasia (BCA) referred tisagenlecleucel with EM disease (both...
In humans receiving intestinal transplantation (ITx), long-term multilineage blood chimerism often develops. Donor T cell macrochimerism (≥4%) frequently occurs without graft-versus-host disease (GVHD) and is associated with reduced rejection. Here we demonstrate that patients had high (GvH) to host-versus-graft (HvG) clonal ratios in their allografts. These GvH clones entered the circulation, where peak levels were declines HvG early after transplant, suggesting reactions may contribute...
Abstract Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral prior studies. We performed phase II multicenter study (NCT03475212) the patients with inborn errors immunity and/or post allogeneic hematopoietic stem transplant using partially-HLA matched VSTs targeting cytomegalovirus, Epstein-Barr virus, or adenovirus. Primary endpoints were feasibility, safety, clinical...
Advances in allogeneic hematopoietic cell transplantation for sickle disease have improved outcomes, but there is limited analysis of healthcare utilization this setting. We hypothesized that, compared to late transplantation, early (at age
BACKGROUND Autologous hematopoietic cell transplantation (auto‐HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B‐cell (DLBCL); however, long‐term outcomes are not well described. METHODS This study analyzed survival, nonrelapse mortality, late effects, subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression‐free ≥2 years after auto‐HCT cHL or DLBCL between 1990 2008. The median age at was 40 years; the follow‐up 10.6 years....
Acute graft-versus-host disease (aGVHD) still remains a major limiting factor following allogeneic stem cell transplantation (AlloSCT) in pediatric recipients. Mycophenolate mofetil (MMF), an uncompetitive selective inhibitor of inosine monophosphate dehydrogenase, is new immunosuppressant agent without mucosal, hepatic, or renal toxicity compared to other prophylactic aGVHD drugs. Although there has been extensive pharmacokinetic (PK) experience with MMF administration solid organ children,...
Summary Immune reconstitution appears to be delayed following myeloablative conditioning (MAC) and umbilical cord blood transplantation (UCBT) in paediatric recipients. Although reduced toxicity (RTC) versus MAC prior allogeneic stem cell is associated with decreased transplant‐related mortality, the effects of RTC UCBT on immune risk graft‐versus‐host disease (GVHD) are unknown. In 88 consecutive recipients UCBT, we assessed recovery immunoglobulin at days +100, 180 365 analysed factors...